Christelle Jost1, Philippe Bidet1, Thibault Carrère2, Patricia Mariani-Kurkdjian2, Stéphane Bonacorsi3. 1. Service de Microbiologie, Centre National de Référence associé, AP-HP, Hôpital Robert Debré, Paris, France Univ Paris Diderot, Sorbonne Paris Cité, Paris, France INSERM, IAME, UMR 1137, F-75018 Paris, France. 2. Service de Microbiologie, Centre National de Référence associé, AP-HP, Hôpital Robert Debré, Paris, France. 3. Service de Microbiologie, Centre National de Référence associé, AP-HP, Hôpital Robert Debré, Paris, France Univ Paris Diderot, Sorbonne Paris Cité, Paris, France INSERM, IAME, UMR 1137, F-75018 Paris, France stephane.bonacorsi@aphp.fr.
Abstract
OBJECTIVES: Antibiotic therapy is not recommended during enterohaemorrhagic Escherichia coli (EHEC) infection. However, the potential benefit of azithromycin has recently been described. This study was conducted to evaluate the macrolide susceptibility of EHEC isolates from France and to analyse the mechanisms of resistance to azithromycin in EHEC. METHODS: Strains from patients with EHEC infections were collected by the associated French National Reference Laboratory for E. coli from 2004 to 2014. Antimicrobial susceptibility testing was performed by disc diffusion and Etest methods. For strains presenting macrolide resistance, antibiotic resistance genes were searched for by PCR. Genetic transfer was performed by conjugation and plasmid analysis was done by Southern-blot hybridization after PFGE. RESULTS: We tested 508 isolates of EHEC. Azithromycin MICs ranged between 0.25 and 16 mg/L (median = 3 mg/L), except for two atypical strains, 34396 and 36493, for which MICs were >256 mg/L. Plasmid transferability of macrolide resistance was demonstrated. Strain 34396, of serotype O106:H18, harboured two macrolide resistance genes [mph(A) and erm(B)] and two other antimicrobial resistance genes (blaDHA-1 for β-lactam resistance and qnrB4 for quinolone resistance). mph(A), blaDHA-1 and qnrB4 were localized on the same plasmid. Strain 36493 belonging to the highly virulent O26:H11 EHEC clonal group harboured a plasmid containing mph(A). CONCLUSIONS: For the first time we describe plasmid-borne macrolide resistance genes in EHEC strains. Dissemination of such plasmids may threaten the potential benefit of azithromycin during the management of patients infected or colonized with EHEC. Determination of azithromycin MICs should be considered prior to its therapeutic use and 16 mg/L may be used as the epidemiological cut-off value.
OBJECTIVES: Antibiotic therapy is not recommended during enterohaemorrhagic Escherichia coli (EHEC) infection. However, the potential benefit of azithromycin has recently been described. This study was conducted to evaluate the macrolide susceptibility of EHEC isolates from France and to analyse the mechanisms of resistance to azithromycin in EHEC. METHODS: Strains from patients with EHEC infections were collected by the associated French National Reference Laboratory for E. coli from 2004 to 2014. Antimicrobial susceptibility testing was performed by disc diffusion and Etest methods. For strains presenting macrolide resistance, antibiotic resistance genes were searched for by PCR. Genetic transfer was performed by conjugation and plasmid analysis was done by Southern-blot hybridization after PFGE. RESULTS: We tested 508 isolates of EHEC. Azithromycin MICs ranged between 0.25 and 16 mg/L (median = 3 mg/L), except for two atypical strains, 34396 and 36493, for which MICs were >256 mg/L. Plasmid transferability of macrolide resistance was demonstrated. Strain 34396, of serotype O106:H18, harboured two macrolide resistance genes [mph(A) and erm(B)] and two other antimicrobial resistance genes (blaDHA-1 for β-lactam resistance and qnrB4 for quinolone resistance). mph(A), blaDHA-1 and qnrB4 were localized on the same plasmid. Strain 36493 belonging to the highly virulent O26:H11 EHEC clonal group harboured a plasmid containing mph(A). CONCLUSIONS: For the first time we describe plasmid-borne macrolide resistance genes in EHEC strains. Dissemination of such plasmids may threaten the potential benefit of azithromycin during the management of patientsinfected or colonized with EHEC. Determination of azithromycin MICs should be considered prior to its therapeutic use and 16 mg/L may be used as the epidemiological cut-off value.
Authors: Sabine Delannoy; Patricia Mariani-Kurkdjian; Hattie E Webb; Stephane Bonacorsi; Patrick Fach Journal: Front Microbiol Date: 2017-09-06 Impact factor: 5.640
Authors: Anna Lena Zogg; Sabrina Simmen; Katrin Zurfluh; Roger Stephan; Sarah N Schmitt; Magdalena Nüesch-Inderbinen Journal: Front Vet Sci Date: 2018-03-27